AR009985A1 - Aminotiofencarboxamidas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen, y un procedimiento para obtener estas preparaciones farmaceuticas - Google Patents
Aminotiofencarboxamidas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen, y un procedimiento para obtener estas preparaciones farmaceuticasInfo
- Publication number
- AR009985A1 AR009985A1 ARP970104736A ARP970104736A AR009985A1 AR 009985 A1 AR009985 A1 AR 009985A1 AR P970104736 A ARP970104736 A AR P970104736A AR P970104736 A ARP970104736 A AR P970104736A AR 009985 A1 AR009985 A1 AR 009985A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical preparations
- procedure
- prepare
- hal
- aminotiofencarboxamidas
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 229940126601 medicinal product Drugs 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- -1 COOA Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 210000000748 cardiovascular system Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Aminotiofencarboxamidas de formula (I) en donde R1, R2 son independientemente H, A, OA, alquenilo, alquinilo, CF3 o Hal, siendo uno de losrestos R1 o R2 siempre H; R1 y R2 juntos, también son alquileno de 3 a 5 átomos de C. R3, R4 representan independientemente H, A, OA, NO2, NH2 o Hal, R3 Y R4juntos también son -O-CH2-CH2-, -O-CH2-O- o -O-CH2-CH2-O-; A, A son independientemente H o alquilo de 1 a 6 átomos de C. R5 es -X-Y; X es CO, CS oSO2. Y es un anillo isocíclicoo heterocíclico saturado o insaturado de 5 a 7 miembros que puede estar no sustituido o mono o disustituido con COOH,COOA,CONH2,CONAA,CONHA,CN,NHSO2A, N(SO2A)2 o SO2A. Hal es F,Cl,Br o I. Y n es 0, 1, 2 o 3, y a sus sales aceptables desde el puntode vista fisiologico. También serefiere a un procedimiento para preparar estos compuestos, al empleo de los mismos para preparar un medicamento, a las preparaciones farmacéuticas que loscontienen y a un procedimiento para obtener estas preparaciones farmacéuticas. Los compuestos de formula (I) y sus sales aceptables desde el punto de vistafisiologico actuan como inhibidores de la fofodiesterasa V y pueden ser empleados para el tratamiento de las enfermedades del sistemacardiocirculatorio y para la terapia delos trastornos de la potencia.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19642451A DE19642451A1 (de) | 1996-10-15 | 1996-10-15 | Aminothiophencarbonsäureamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR009985A1 true AR009985A1 (es) | 2000-05-17 |
Family
ID=7808775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970104736A AR009985A1 (es) | 1996-10-15 | 1997-10-15 | Aminotiofencarboxamidas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen, y un procedimiento para obtener estas preparaciones farmaceuticas |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US6143777A (es) |
| EP (1) | EP0934301B1 (es) |
| JP (1) | JP4243352B2 (es) |
| KR (1) | KR100479811B1 (es) |
| CN (1) | CN1110493C (es) |
| AR (1) | AR009985A1 (es) |
| AT (1) | ATE202347T1 (es) |
| AU (1) | AU725741B2 (es) |
| BR (1) | BR9712321A (es) |
| CA (1) | CA2268886C (es) |
| CZ (1) | CZ297253B6 (es) |
| DE (2) | DE19642451A1 (es) |
| DK (1) | DK0934301T3 (es) |
| ES (1) | ES2159851T3 (es) |
| GR (1) | GR3036341T3 (es) |
| HU (1) | HUP9904703A3 (es) |
| NO (1) | NO991776L (es) |
| PL (1) | PL192109B1 (es) |
| PT (1) | PT934301E (es) |
| RU (1) | RU2184731C2 (es) |
| SI (1) | SI0934301T1 (es) |
| SK (1) | SK283807B6 (es) |
| TW (1) | TW438791B (es) |
| WO (1) | WO1998016521A1 (es) |
| ZA (1) | ZA979199B (es) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6727258B2 (en) * | 1997-10-29 | 2004-04-27 | King Pharmaceutical Research & Development, Inc. | Allosteric adenosine receptor modulators |
| US6410584B1 (en) | 1998-01-14 | 2002-06-25 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells with indole derivatives |
| JP2002518471A (ja) * | 1998-06-19 | 2002-06-25 | ノバルティス アクチエンゲゼルシャフト | ピリミジノン誘導体の製法 |
| US6200771B1 (en) | 1998-10-15 | 2001-03-13 | Cell Pathways, Inc. | Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia |
| US6133271A (en) * | 1998-11-19 | 2000-10-17 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives |
| US6187779B1 (en) | 1998-11-20 | 2001-02-13 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives |
| US6369092B1 (en) | 1998-11-23 | 2002-04-09 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to substituted benzimidazole derivatives |
| US6034099A (en) * | 1998-11-24 | 2000-03-07 | Cell Pathways, Inc. | Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones |
| US6486155B1 (en) | 1998-11-24 | 2002-11-26 | Cell Pathways Inc | Method of inhibiting neoplastic cells with isoquinoline derivatives |
| US6077842A (en) * | 1998-11-24 | 2000-06-20 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives |
| US6020379A (en) * | 1999-02-19 | 2000-02-01 | Cell Pathways, Inc. | Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia |
| US6479493B1 (en) | 2001-08-23 | 2002-11-12 | Cell Pathways, Inc. | Methods for treatment of type I diabetes |
| JP2005504806A (ja) * | 2001-09-21 | 2005-02-17 | スミスクライン・ビーチャム・コーポレイション | 化合物 |
| DE60229975D1 (de) * | 2001-10-04 | 2009-01-02 | Smithkline Beecham Corp | Nf-kb-inhibitoren |
| US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| US7276529B2 (en) | 2002-03-20 | 2007-10-02 | Celgene Corporation | Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
| US7208516B2 (en) | 2002-03-20 | 2007-04-24 | Celgene Corporation | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
| US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
| WO2004009581A1 (ja) * | 2002-07-24 | 2004-01-29 | Mitsui Chemicals, Inc. | ２−アルキル−３−アミノチオフェン誘導体の製造法 |
| US7179836B2 (en) * | 2002-09-20 | 2007-02-20 | Smithkline Beecham Corporation | Chemical compounds |
| DE602004031777D1 (en) * | 2004-01-05 | 2011-04-21 | Astrazeneca Ab | Thiophenderivate als chk-1-inhibitoren |
| FR2875807B1 (fr) * | 2004-09-30 | 2006-11-17 | Servier Lab | Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
| MX2007011670A (es) * | 2005-03-23 | 2007-11-15 | Actelion Pharmaceuticals Ltd | Derivados de benzo(c) tiofeno hidrogenados como inmunomoduladores. |
| JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス，インコーポレイティド | ムスカリン性受容体調節による神経発生 |
| EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| JP2009512711A (ja) | 2005-10-21 | 2009-03-26 | ブレインセルス，インコーポレイティド | Ｐｄｅ阻害による神経新生の調節 |
| JP2009513672A (ja) | 2005-10-31 | 2009-04-02 | ブレインセルス，インコーポレイティド | 神経発生のｇａｂａ受容体媒介調節 |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| WO2007134077A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| MX2009002496A (es) * | 2006-09-08 | 2009-07-10 | Braincells Inc | Combinaciones que contienen un derivado de 4-acilaminopiridina. |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| CA2734500A1 (en) * | 2008-08-27 | 2010-03-11 | Calcimedica Inc. | Compounds that modulate intracellular calcium |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| US20150119399A1 (en) | 2012-01-10 | 2015-04-30 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
| RU2503671C1 (ru) * | 2012-07-31 | 2014-01-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Пермский государственный национальный исследовательский университет" | (Z)-2-[(3-КАРБАМОИЛ-4,5,6,7-ТЕТРАГИДРОБЕНЗО[b]ТИЕН-2-ИЛ)АМИНО]-4-(4-R-ФЕНИЛ)-4-ОКСОБУТ-2-ЕНОВЫЕ КИСЛОТЫ, ОБЛАДАЮЩИЕ АНАЛЬГЕТИЧЕСКОЙ АКТИВНОСТЬЮ |
| RU2501795C1 (ru) * | 2012-10-01 | 2013-12-20 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Пермский государственный национальный исследовательский университет" | N-R-АМИДЫ (Z)-2[(3-ЭТОКСИКАРБОНИЛ)-4,5,6,7-ТЕТРАГИДРОБЕНЗО[b]ТИЕН-2-ИЛ)АМИНО]-4-ФЕНИЛ-4-ОКСОБУТ-2-ЕНОВЫХ КИСЛОТ, ОБЛАДАЮЩИЕ АНАЛЬГЕТИЧЕСКОЙ АКТИВНОСТЬЮ |
| EP3157520B1 (en) | 2014-06-23 | 2019-09-04 | Celgene Corporation | Apremilast for the treatment of a liver disease or a liver function abnormality |
| CN118791407A (zh) | 2018-05-22 | 2024-10-18 | 奥索生物公司 | 亚磺酰基氨基苯甲酰胺以及磺酰基氨基苯甲酰胺衍生物 |
| RU2722176C1 (ru) * | 2019-09-06 | 2020-05-28 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" | (z)-2((4-r1-5-r2-3-(этоксикарбонил)тиофен-2-ил)амино)-4-оксо-4-r3-бут-2-еновые кислоты, обладающие противомикробной активностью |
| WO2022020714A1 (en) * | 2020-07-24 | 2022-01-27 | Inipharm, Inc. | Thiophene hsd17b13 inhibitors and uses thereof |
| MX2023005550A (es) | 2020-11-13 | 2023-07-18 | Inipharm Inc | Inhibidores de diclorofenol hsd17b13 y usos de los mismos. |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5075310A (en) * | 1988-07-01 | 1991-12-24 | Smith Kline & French Laboratories, Ltd. | Pyrimidone derivatives as bronchodilators |
| US5047555A (en) * | 1988-12-13 | 1991-09-10 | Tanabe Seiyaku Co., Ltd. | 4-aminophenol derivatives and processes for preparing the same |
| US5753692A (en) * | 1992-02-19 | 1998-05-19 | Industrial Technology Research Institute | Medicinal thiophene compounds |
| US5356926A (en) * | 1992-02-24 | 1994-10-18 | Warner-Lambert Company | 3-alkyloxy-, aryloxy-, or arylalkyloxy-benzo [β]thiophene-2-carboxamides as inhibitors of cell adhesion |
| DE4230755A1 (de) * | 1992-09-14 | 1994-03-17 | Schering Ag | Verwendung von PDE-Inhibitoren bei der Behandlung von Nieren- und Ureter-Erkrankungen |
| DE4233198A1 (de) * | 1992-10-02 | 1994-04-07 | Bayer Ag | Substituierte Thiophencarbonsäureamide |
| DK148292D0 (da) * | 1992-12-09 | 1992-12-09 | Lundbeck & Co As H | Forbindelser |
| GB9309324D0 (en) * | 1993-05-06 | 1993-06-16 | Bayer Ag | Venzofuranyl-and-thiophenyl-alkanecarboxyclic acids derivatives |
| DE4317076A1 (de) * | 1993-05-21 | 1994-11-24 | Bayer Ag | Benzthiophencarbonsäureamid-S-oxide |
| DE69507197T2 (de) * | 1994-05-31 | 1999-05-27 | Bayer Ag, 51373 Leverkusen | Aminobenzofuryl- und -thienylderivate |
| US5863936A (en) * | 1995-04-18 | 1999-01-26 | Geron Corporation | Telomerase inhibitors |
| WO1998015545A1 (en) * | 1996-10-08 | 1998-04-16 | Eli Lilly And Company | New serotonin 5-ht1f agonists |
| US5783597A (en) * | 1997-03-04 | 1998-07-21 | Ortho Pharmaceutical Corporation | 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use |
-
1996
- 1996-10-15 DE DE19642451A patent/DE19642451A1/de not_active Withdrawn
-
1997
- 1997-10-06 TW TW086114589A patent/TW438791B/zh active
- 1997-10-08 BR BR9712321-8A patent/BR9712321A/pt not_active Application Discontinuation
- 1997-10-08 ES ES97912140T patent/ES2159851T3/es not_active Expired - Lifetime
- 1997-10-08 AT AT97912140T patent/ATE202347T1/de not_active IP Right Cessation
- 1997-10-08 SI SI9730192T patent/SI0934301T1/xx unknown
- 1997-10-08 RU RU99109576/04A patent/RU2184731C2/ru not_active IP Right Cessation
- 1997-10-08 SK SK432-99A patent/SK283807B6/sk unknown
- 1997-10-08 CZ CZ0124099A patent/CZ297253B6/cs not_active IP Right Cessation
- 1997-10-08 CA CA002268886A patent/CA2268886C/en not_active Expired - Fee Related
- 1997-10-08 HU HU9904703A patent/HUP9904703A3/hu unknown
- 1997-10-08 EP EP97912140A patent/EP0934301B1/de not_active Expired - Lifetime
- 1997-10-08 WO PCT/EP1997/005531 patent/WO1998016521A1/de not_active Ceased
- 1997-10-08 DE DE59703869T patent/DE59703869D1/de not_active Expired - Lifetime
- 1997-10-08 US US09/284,501 patent/US6143777A/en not_active Expired - Fee Related
- 1997-10-08 KR KR10-1999-7003246A patent/KR100479811B1/ko not_active Expired - Fee Related
- 1997-10-08 PT PT97912140T patent/PT934301E/pt unknown
- 1997-10-08 AU AU49451/97A patent/AU725741B2/en not_active Ceased
- 1997-10-08 JP JP51798698A patent/JP4243352B2/ja not_active Expired - Fee Related
- 1997-10-08 PL PL332802A patent/PL192109B1/pl unknown
- 1997-10-08 DK DK97912140T patent/DK0934301T3/da active
- 1997-10-08 CN CN97198839A patent/CN1110493C/zh not_active Expired - Fee Related
- 1997-10-14 ZA ZA9709199A patent/ZA979199B/xx unknown
- 1997-10-15 AR ARP970104736A patent/AR009985A1/es not_active Application Discontinuation
-
1999
- 1999-04-14 NO NO991776A patent/NO991776L/no not_active Application Discontinuation
-
2001
- 2001-08-07 GR GR20010401193T patent/GR3036341T3/el not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR009985A1 (es) | Aminotiofencarboxamidas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen, y un procedimiento para obtener estas preparaciones farmaceuticas | |
| AR008504A1 (es) | Tienopirimidinas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen, y un procedimiento para obtener estas preparaciones farmaceuticas | |
| AR009052A1 (es) | Tienopirimidinas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen y un procedimiento para obtener estas preparaciones farmaceuticas | |
| AR010962A1 (es) | Tienopirimidinas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen, y un procedimiento para obtener estas preparaciones farmaceuticas. | |
| MX9207382A (es) | Nuevos compuestos que tienen actividad terapeutica intermediarios para su preparacion, proceso para obtencion de tales compuestos y formulacion farmaceutica que los contiene. | |
| AR016762A1 (es) | Compuestos del acido 4-bromo o 4-yodo fenilamino benzohidroxamico, formulaciones farmaceuticas y uso del mismo | |
| DK0490772T3 (da) | 1,4-disubstituerede piperaziner, fremgangsmåde til fremstilling heraf og farmaceutiske midler, der indeholder dem | |
| PA8432901A1 (es) | Compuestos de piridilpirrol | |
| DK0513702T3 (da) | Melatoninderivater til anvendelse til behandling af søvnlidelser og til præ-anæstetisk medicinering | |
| ES2054860T3 (es) | Nuevos derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion, asi como a su utilizacion como medicamentos. | |
| GB1069343A (en) | Propanolamine derivatives | |
| AR024819A1 (es) | Derivados de la n-(indolcarbonil)-piperazina, un procedimiento para su preparacion, su empleo para preparar un medicamento, los medicamentos a base de los mismos y las preparaciones farmaceuticas que los contienen. | |
| ES2041705T3 (es) | Procedimiento para la preparacion de 1-(4-hidroxi-3,5-di-terc-butil-benzoil)-homopiperazina y sus derivados. | |
| ES8201167A1 (es) | Procedimiento para la obtencion de derivados de cefalospori-nas | |
| MX9304467A (es) | Nuevos derivados fosfonados de ariletanolaminas, procedimiento para su preparacion y composiciones farmaceuticas y veterinarias que los contienen. | |
| ES2046193T3 (es) | Un procedimiento para la preparacion de un compuesto de imidazolidinona. | |
| ES2091183T3 (es) | Metodo para mejorar el sueño. | |
| AR001769A1 (es) | Benzamida enterocinética composiciones farmacéuticas que las contienen procedimiento para la preparación de dichas composiciones farmacéuticas el uso de dichos compuestos para la manufactura de medicamentos y un procedimiento para su preparación | |
| ES2038216T3 (es) | Procedimiento para la preparacion de 5-(3-alquil-5-t-butil-4-hidroxi-fenil)-2-amino-6h-1,3,4-tiadazinas y su empleo. | |
| AR024818A1 (es) | Derivados de la n-(indolcarbonil)-piperazina, un procedimiento para su preparacion, su empleo para preparar un medicamento, los medicamentos a base de losmismos y las preparaciones farmaceuticas que los contienen. | |
| YU233090A (sh) | Karbamoilni derivati | |
| ES2043943T3 (es) | Procedimiento para la preparacion de compuestos con actividad analgesica central. | |
| DE3786256D1 (de) | Antifolat-mittel. | |
| ES2041815T3 (es) | Un procedimiento para la obtencion de derivados de ornitina 5-sustituidos. | |
| MX9303574A (es) | Compuestos heterociclicos que son inhibidores de la enzima aromatasa, proceso para su preparacion ycomposiciones farmaceuticas que los contienen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |